Clinical Trials Logo

Clinical Trial Summary

Blood perfusion insufficiency and hypoxia are the main causes of drug resistance to chemotherapy in breast cancer. Increasing blood perfusion can improve drug delivery. The cavitation effect of ultrasound-stimulated microbubbles (USMBs) is known to enhance tumor blood perfusion, so we conducted a prospective human study to investigate the effects of USMBs on hemoperfusion in invasive breast cancer (IBC).


Clinical Trial Description

patients with IBC were selected from the breast surgery department of our hospital. To induce an enhanced perfusion effect, IBC tumors were treated with SonoVue® microbubbles (MBs) stimulated by ultrasound, with a mechanical index (MI) of 0.2-0.3; 1 mL of SonoVue® MBs were injected at 3.5-min intervals three times for a USMB treatment lasting 10 min. The contrast-enhanced ultrasound (CEUS) parameters peak intensity (PI), area under the curve (AUC), and perfusion area were used to evaluate the changes in blood perfusion. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06158217
Study type Observational
Source Beijing Friendship Hospital
Contact Yunyun Dong, MS
Phone 01063138576
Email 13811652027@163.com
Status Recruiting
Phase
Start date September 29, 2022
Completion date May 6, 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03595592 - Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer Phase 3
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Active, not recruiting NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Phase 2
Completed NCT02773784 - Comparison of CNB and Surgical Specimens for ER, PgR, HER2 Status and Ki67 Index in Invasive Breast Cancer.
Recruiting NCT01509781 - Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study Phase 3
Completed NCT04478669 - Digital Breast Tomosynthesis (DBT) to Improve Assessment of Resection Margins in Invasive Breast Cancer
Recruiting NCT04553770 - Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer Phase 2
Recruiting NCT04677816 - Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients Phase 2
Terminated NCT01934335 - Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer Phase 2
Completed NCT00507611 - Axillary Lymph Node Status After Completion of Preoperative Neoadjuvant Systemic Chemotherapy in Patients N/A
Completed NCT00581750 - Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ
Completed NCT03304171 - Overall Diet Quality and Breast Cancer Risk N/A
Completed NCT03709186 - Radiomic Markers for Breast Cancer Metastasis and Treatment Response Using MRI
Terminated NCT03361800 - Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC Early Phase 1
Recruiting NCT04648904 - Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer Early Phase 1
Recruiting NCT06328465 - fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases N/A
Active, not recruiting NCT03109522 - Axillary Reverse Mapping (ARM) Technique N/A
Recruiting NCT03987555 - Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Recruiting NCT03497702 - Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer Phase 2
Recruiting NCT05795101 - TRUDI: TDXD+Durva in HER2+/Low IBC Phase 2